This roundtable series evaluates radioligand therapy in patients with previously treated metastatic castration-resistant prostate cancer with positive prostate-specific membrane antigen, as discussed by participants at virtual live events.
Targeted Radioligand Therapy Shows Efficacy in PSMA-Positive mCRPC
Michael J. Morris, MD, discusses the results of the VISION trial of 177-lutetium-PSMA-61 in patients with metastatic castration-resistant prostate cancer.
Expert Discusses When to Perform PSMA PET Imaging for Metastatic CRPC
Daniel J. George, MD, discusses why he considers using prostate-specific membrane antigen imaging early in treatment of patients with castration-resistant prostate cancer.
2 Clarke Drive Cranbury, NJ 08512